TCRX TScan Therapeutics Inc
Price (delayed)
$1.27
Market cap
$71.87M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.14
Enterprise value
-$14.47M
Highlights
The equity has soared by 60% YoY and by 5% from the previous quarter
TScan Therapeutics's quick ratio has increased by 24% YoY but it has decreased by 15% QoQ
The EPS has decreased by 19% QoQ but it has increased by 16% YoY
TScan Therapeutics's revenue has shrunk by 87% YoY and by 70% QoQ
TCRX's gross profit has plunged by 87% YoY and by 70% from the previous quarter
Key stats
What are the main financial stats of TCRX
Market
Valuations
Earnings
Shares outstanding
56.59M
Market cap
$71.87M
Enterprise value
-$14.47M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.28
Price to sales (P/S)
50.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-5.14
Revenue
$2.82M
Gross profit
$2.82M
Operating income
-$134.82M
Net income
-$127.5M
EBIT
-$123.85M
EBITDA
-$119.74M
Free cash flow
-$114.65M
Per share
Balance sheet
Liquidity
EPS
-$1.14
EPS diluted
-$1.14
Free cash flow per share
-$1.02
Book value per share
$4.52
Revenue per share
$0.03
TBVPS
$3.31
Total assets
$371.12M
Total liabilities
$130.15M
Debt
$97.38M
Equity
$240.97M
Working capital
$256.77M
Debt to equity
0.4
Current ratio
8.14
Quick ratio
8.21
Net debt/EBITDA
0.72
Margins
Efficiency
Dividend
EBITDA margin
-4,252.1%
Gross margin
100%
Net margin
-4,527.7%
Operating margin
-4,787.7%
Return on assets
-38.2%
Return on equity
-60.1%
Return on invested capital
-57.9%
Return on capital employed
-37%
Return on sales
-4,397.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TCRX stock price
How has the TScan Therapeutics stock price performed over time
Intraday
0%
1 week
-12.41%
1 month
-39.52%
1 year
-82.36%
YTD
-58.22%
QTD
-7.97%
Financial performance
How have TScan Therapeutics's revenue and profit performed over time
Revenue
$2.82M
Gross profit
$2.82M
Operating income
-$134.82M
Net income
-$127.5M
Gross margin
100%
Net margin
-4,527.7%
TScan Therapeutics's revenue has shrunk by 87% YoY and by 70% QoQ
TCRX's gross profit has plunged by 87% YoY and by 70% from the previous quarter
The company's operating income fell by 44% YoY and by 13% QoQ
The company's net income fell by 43% YoY and by 15% QoQ
Growth
What is TScan Therapeutics's growth rate over time
Valuation
What is TScan Therapeutics stock price valuation
P/E
N/A
P/B
0.28
P/S
50.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-5.14
The EPS has decreased by 19% QoQ but it has increased by 16% YoY
The price to book (P/B) is 81% lower than the last 4 quarters average of 1.5
The equity has soared by 60% YoY and by 5% from the previous quarter
TScan Therapeutics's revenue has shrunk by 87% YoY and by 70% QoQ
The price to sales (P/S) is 30% lower than the last 4 quarters average of 72.3
Efficiency
How efficient is TScan Therapeutics business performance
TScan Therapeutics's ROIC has decreased by 15% YoY and by 8% from the previous quarter
The company's return on assets fell by 13% YoY and by 6% QoQ
TScan Therapeutics's ROE has decreased by 2.4% from the previous quarter
Dividends
What is TCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TCRX.
Financial health
How did TScan Therapeutics financials performed over time
The total assets is 185% greater than the total liabilities
The total assets has increased by 36% year-on-year and by 7% since the previous quarter
TCRX's current ratio is up by 25% year-on-year but it is down by 15% since the previous quarter
TScan Therapeutics's debt is 60% lower than its equity
The equity has soared by 60% YoY and by 5% from the previous quarter
The debt to equity has declined by 34% year-on-year but it has increased by 2.6% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.